Skip to content
RDL Network logo
791MO Clinical and tumor characteristics of patients (pts) with recurrence after pathologic response upon neoadjuvant ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma — J.M. Versluis (2022) | RDL Network